A prospective cohort study on postoperative radiotherapy with TomoDirect using simultaneous integrated boost technique in early breast cancer

Radiation Oncology

Jong Hoon Lee²  Hyun Joo Choi¹  Dae Gyu Kang²  Mi Joo Chung²  Young Jin Suh³  Sung Hwan Kim²  Hyo Chun Lee² 

[1] Department of Hospital Pathology, St. Vincent¿s Hospital, The Catholic University of Korea, Seoul, Republic of Korea;Department of Radiation Oncology, St. Vincent¿s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, 442-723, 93-6, Ji-dong, Paldal-gu, Suwon, Kyeonggi-do, Republic of Korea;Department of Surgery, St. Vincent¿s Hospital, The Catholic University of Korea, Seoul, Republic of Korea

关键词: Toxicity;    TomoTherapy;    Radiotherapy;    Breast cancer;   

Others  :  1151003
DOI  :  10.1186/s13014-014-0244-0

 received in 2014-08-29, accepted in 2014-10-30,  发布年份 2014

【 摘 要 】

Purpose

To evaluate the technical feasibility and toxicity of TomoDirect in breast cancer patients who received radiotherapy after breast-conserving surgery.

Methods

155 consecutive patients with breast carcinoma in situ or T1-2 breast cancer with negative lymph node received breast irradiation with TomoDirect using simultaneous integrated boost technique in the prospective cohort study. A radiation dose of 50.4 Gy and 57.4 Gy in 28 fractions was prescribed to the ipsilateral breast and tumor bed, respectively. Dosimetric parameters of target and organ at risk and acute complication were assessed prospectively.

Results

The mean dose for the tumor bed is 58.90 Gy. The mean values of V_{54.53Gy (95% of the prescribed dose)}, V_{63.14Gy (110% of the prescribed dose)}, and V_{66.01Gy (115% of the prescribed dose)} were 99.97%, 1.26%, and 0%, respectively. The mean value of radiation conformality index was 1.01. The mean value of radical dose homogeneity index was 0.89. The average dose irradiated to the ipsilateral lung, heart, and contralateral breast was 4.72 Gy, 1.09 Gy, and 0.19 Gy, respectively. The most common toxicity was dermatitis. During breast irradiation, grade 2 and 3 dermatitis occurred in 41 (26.5%) and 6 (3.9%) of the 155 patients, respectively. Two patients had arm lymphedema during breast irradiation. Two patients had grade 2 pneumonitis 1 month after breast irradiation.

Conclusions

Radiotherapy using TomoDirect in early breast cancer patients showed acceptable toxicities and optimal results in terms of target coverage and organ at risk sparing.

【 授权许可】

   
2014 Lee et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Jung KW, Won YJ, Kong HJ, Oh CM, Lee DH, Lee JS: Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2011. Cancer Res Treat 2014, 46:109-123.
• [2]Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH, Wolmark N: Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002, 347:1233-1241.
• [3]Franceschini D, Paiar F, Meattini I, Agresti B, Pasquetti EM, Greto D, Bonomo P, Marrazzo L, Casati M, Livi L, Biti G: Simultaneous integrated boost-intensity-modulated radiotherapy in head and neck cancer. Laryngoscope 2013, 123:E97-E103.
• [4]Chung Y, Yoon HI, Kim YB, Ahn SK, Keum KC, Suh CO: Radiation pneumonitis in breast cancer patients who received radiotherapy using the partially wide tangent technique after breast conserving surgery. J Breast Cancer 2012, 15:337-343.
• [5]Reynders T, Tournel K, De Coninck P, Heymann S, Vinh-Hung V, Van Parijs H, Duchateau M, Linthout N, Gevaert T, Verellen D, Storme G: Dosimetric assessment of static and helical TomoTherapy in the clinical implementation of breast cancer treatments. Radiother Oncol 2009, 93:71-79.
• [6]Borca VC, Franco P, Catuzzo P, Migliaccio F, Zenone F, Aimonetto S, Peruzzo A, Pasquino M, Russo G, La Porta MR, Cante D, Sciacero P, Girelli G, Ricardi U, Tofani S: Does TomoDirect 3DCRT represent a suitable option for post-operative whole breast irradiation? A hypothesis-generating pilot study.Radiat Oncol 2012, 7:211.
• [7]Saibishkumar EP, MacKenzie MA, Severin D, Mihai A, Hanson J, Daly H, Fallone G, Parliament MB, Abdulkarim BS: Skin-sparing radiation using intensity-modulated radiotherapy after conservative surgery in early-stage breast cancer: a planning study. Int J Radiat Oncol Biol Phys 2008, 2:485-491.
• [8]Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Kelsen DP: INT 0123 (Radiation Therapy Oncology Group 94¿05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002, 20:1167-1174.
• [9]Donato V, Cianciulli M, Fouraki S, Vigna L, Rocco A, Raffetto N, Bellocchi G: Helical tomotherapy: an innovative radiotherapy technique for the treatment of locally advanced oropharynx and inoperable oral cavity carcinoma.Radiat Oncol 2013, 8:210.
• [10]Macias VA, Blanco ML, Perez-Romasanta LA: Initial experience with stereotactic body radiation therapy for localized prostate cancer using helical tomotherapy. Clin Transl Oncol 2014, 16:380-385.
• [11]Park HJ, Kim KJ, Park SH, Kay CS, Oh JS: Early CT findings of tomotherapy-induced radiation pneumonitis after treatment of lung malignancy. Am J Roentgenol 2009, 193:W209-W213.
• [12]Seppenwoolde Y, Lebesque JV, de Jaeger K, Belderbos JS, Boersma LJ, Schilstra C, Henning GT, Hayman JA, Martel MK, Ten Haken RK: Comparing different NTCP models that predict the incidence of radiation pneumonitis. Normal tissue complication probability. Int J Radiat Oncol Biol Phys 2003, 55:724-735.
• [13]Marks LB, Yorke ED, Jackson A, Ten Haken RK, Constine LS, Eisbruch A, Bentzen SM, Nam J, Deasy JO: Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys 2010, 76:S10-S19.
• [14]Graham MV, Purdy JA, Emami B, Harms W, Bosch W, Lockett MA, Perez CA: Clinical dose volume histogram analysis for pneumonitis after 3D treatment for non¿small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 1999, 45:323-329.
• [15]Hurkmans CW, Cho BC, Damen E, Zijp L, Mijnheer BJ: Reduction of cardiac and lung complication probabilities after breast cancer irradiation. Radiother Oncol 2002, 62:163-171.
• [16]Boice JD Jr, Harvey EB, Blettner M, Stovall M, Flannery JT: Cancer in the contralateral breast after radiotherapy for breast cancer. N Engl J Med 1992, 326:781-785.
• [17]Chung MJ, Suh YJ, Lee HC, Kang DG, Kim EJ, Kim SH, Lee JH: Tumor bed volumetric changes during breast irradiation for the patients with breast cancer. Radiat Oncol J 2013, 31:228-233.
• [18]Zucali R, Luini A, Del Vecchio M, Sacchini V, Sverzellati E, Stucchi C, Banfi A, Veronesi U: Contralateral breast cancer after limited surgery plus radiotherapy of early mammary tumors. Eur J Surg Oncol 1987, 13:413-417.